GvHD therapy with in vitro expanded donor regulatory T cells (B07)

• Subject Area: Hematology, Oncology ; Immunology
• Term: since 2018
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 324392634

We previously showed that donor CD4+CD25+Foxp3+ regulatory T cells (Treg) prevent lethal acute GvHD after MHC-mismatched allo-HSCT in murine models. We now found that they also ameliorate ongoing GvHD and the prerequisites for efficacious GvHD therapy are studied in this project. For this purpose, the migration pattern of in vitro expanded donor Treg is examined, their organ-specific T cell receptor (TCR) repertoire selection and their site-specific functional status in the presence or absence of intestinal microbiota. Finally, we investigate whether their therapeutic efficacy in GvHD can be enhanced by overexpression of alloreactive TCR or tissue-specific chimeric antigen receptors (CAR).

• DFG Programme: CRC/Transregios
• Subproject of: TRR 221: Modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation
• Applicant Institution: Universität Regensburg
• Project Heads: Professor Dr. Matthias Edinger; Privatdozentin Dr. Petra Hoffmann; Professor Dr. Michael Rehli